Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- Amarantus Bioscience Holdings, Inc. has formed a wholly-owned subsidiary MANF Therapeutics, Inc. for the purpose of the continued pre-clinical development of the internally discovered MANF program in development for the treatment of ophthalmological disorders, including the orphan indications retinitis pigmentosa (RP) and retinal artery occlusion (RAO), in addition to glaucoma and Parkinson's disease.
- ThromboGenics has reportedly achieved an important milestone in the advancing of the pre-clinical development of its THR-149 — a novel plasma kallikrein inhibitor, which the company is developing for the treatment of Diabetic Macular Edema (DME). Following today’s announcement, ThromboGenics will reportedly now start pivotal tox studies which are a last step before starting the clinical development which is expected for early 2018.
- Clearside Biomedical, Inc. has completed enrollment of an exploratory clinical trial (the “HULK” trial) of CLS-TA for suprachoroidal administration — its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, with or without intravitreal Eylea® (aflibercept), for the treatment of DME. Clearside currently expects to report preliminary results from the HULK trial in the second half of 2017.
- Eyevensys has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to advance its technology into clinical development. Eyevensys is reportedly developing its proprietary EyeCET platform — the first non-viral gene expression technology that enables the safe, local, sustained production of therapeutic proteins in the eye to address a wide range of ophthalmic diseases.
- Mentor Capital, Inc. — a public operating company that acquires and provides liquidity for medical and social use cannabis companies — recently announced it has initiated funding for its GlauCanna venture for the use of medical marijuana in the treatment of glaucoma patients.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.